Continuous Glucose Monitoring Adoption in the United Kingdom – An Economic and Policy Perspective
Abstract:
Overview
Continuous glucose monitoring (CGM) technology provides real-time glucose concentration data to people with diabetes. The data enable timely treatment decisions that can lead to avoidance or mitigation of hypoglycaemia, with potential cost savings. This commentary discusses CGM implementation and funding policies in the UK, and regional disparities that confront many people with diabetes who could benefit from the technology.
Keywords
Continuous glucose monitoring,
commissioning, hypoglycaemia
Article:
Article Information:
Disclosure
Nick Oliver has received research
support from Dexcom, Inc. This article is a short
opinion piece and has not been submitted to
external peer reviewers, but was reviewed by the
editorial board for accuracy before publication.
Correspondence
Nick Oliver, Section of
Diabetes, Endocrinology and Metabolism, Faculty of
Medicine, Imperial College, Du Cane Road, London,
W12 0HS, UK. E: Nick.oliver@imperial.ac.uk
Support
The publication of this article was
supported by Dexcom, Inc. The views and opinions
expressed are those of the author and do not
necessarily reflect those of Dexcom, Inc.
Access
Open Access: This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original.
Received
2017-07-03T00:00:00